Psychoactive substances are becoming increasingly available to individuals for treating mental health disorders and enhancing cognition, as well as for purposes of creativity, inner exploration, and enjoyment. A new review published in the British Journal of Pharmacology looks at how these products may provide benefits, as well as how their ease of accessibility is raising a variety of concerns.
Barbara Sahakian, FMedSci DSc, and her colleagues at the University of Cambridge in the United Kingdom address these issues by summarizing studies that have looked into the effects of psychoactive substances in healthy individuals and have explored the characteristics and motivations of users. The review also considers safety, ethical, and regulatory concerns related to the increasing use of these substances, which include stimulant-type drugs (e.g., synthetic cathinones, piperazines, phenethylamines), hallucinogens (e.g., tryptamines), cannabis-like compounds, dissociative drugs (e.g., arylcyclohexylamines, nitrous oxide), sedatives/hypnotics, and opioids.
Various studies highlighted in the review have demonstrated that cognitive-enhancing drugs can indeed moderately enhance cognitive performance in healthy individuals and that the stimulant modafinil may be beneficial to certain populations such as sleep-deprived doctors and shift workers. Therefore, the advantages of these drugs in healthy people should be considered and researched further. It will also be important to consider the negative factors that may drive people to seek cognitive enhancement, such as stress and increasing demands in the workplace. In addition, ethical issues of coercion and fairness, safety issues, and societal values and views should not be overlooked.
“The increasing lifestyle use of psychoactive drugs by healthy people is changing society as we know it,” said Prof. Sahakian. “We need to have a conversation about the reasons people to choose to enhance and ensure that enhancement is not seen as a replacement to the health and wellbeing of the population."
In terms of safety, concerns include use in children and adolescents whose brains are still in development. Also, using the drug without consulting a medical doctor may put some individuals at risk if the drug is counter-indicated for them, for example due to high blood pressure or other medications they may be taking that may result in drug-drug interactions. In addition, there are no long-term safety and efficacy studies, and many people are purchasing these drugs over the Internet without assurances of content and quality control.
“The long-term effects on physical and mental health remain to be determined. More research is needed into these substances and the patterns of their use to better understand their acute and long-term health effects and to establish effective harm reduction strategies,” said lead author Camilla d’Angelo, PhD.
A related BBC documentary entitled, ‘Study drugs and young people,’ recently aired on April 18 and featured British Pharmacological Society member Dr Alistair Jennings.
Dawn Peters (US) +1 781-388-8408
Follow us on Twitter @WileyNews
Full citation: “Lifestyle use of drugs by healthy people for enhancing cognition, creativity, motivation and pleasure.” Laure-Sophie Camilla d’Angelo, George Savulich and Barbara J. Sahakian. British Journal of Pharmacology; Published Online: April 21, 2017 (DOI:
URL Upon Publication: http://doi.wiley.com/10.1111/bph.13813
Author Contact: Craig Brierley, Head of Research Communications at the University of Cambridge, at Craig.Brierley@admin.cam.ac.uk or +44 1223 766205. Dr. George Savulich (+44 1223 336798) is also available.
About the Journal
The British Journal of Pharmacology is a broad-based journal giving leading international coverage of all aspects of pharmacology research. Its scope includes all aspects of pharmacology from hypothesis generation and target validation through to model development, safety pharmacology and to early translational research. BJP’s 2015 Impact Factor is 5.259, and as such it is a leading general research pharmacology journal (Thomson Reuters Science Citation Index).
About The British Pharmacological Society
The British Pharmacological Society is a charity with a mission to promote and advance the whole spectrum of pharmacology. Founded in 1931, it is now a global community at the heart of pharmacology, with over 3,500 members from more than 60 countries worldwide. The Society leads the way in the research and application of pharmacology around the world through its scientific meetings, educational resources and peer-reviewed journals: the British Journal of Clinical Pharmacology, Pharmacology Research & Perspectives, and the British Journal of Pharmacology, which includes the Concise Guide to PHARMACOLOGY, featuring open access overviews of the key properties of over 1,700 human therapeutic targets and their drugs, and links to www.guidetopharmacology.org.
Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at www.wiley.com.